Masimo Q2 Revenue Outlook Miss; Citigroup Bullish On BeiGene
- July 18th, 2023
- 257 views
Shares of Masimo Corporation (Nasdaq: MASI) experienced a significant drop of over 20% in after-hours trading following the release of preliminary revenue results that fell below expectations.
The company anticipates its consolidated revenue for the second quarter of 2023 to range from $453 million to $457 million, which is notably lower than the consensus estimate of $553.23 million.
In response to the disappointing Q2 revenues, Masimo is implementing cost-cutting measures for the second half of the year.
$MASI was trading at $110.00, down $37.16 (-25.25%) in after-hours
In other news, BeiGene, Ltd. (Nasdaq: BGNE), a leading biopharmaceutical company specializing in cancer treatment, received coverage initiation from Citigroup with a Buy rating and a price target of $275.
Based on Monday's closing price of $197.90, the indicated price target suggests a potential upside of $77.10 or approximately 38.87% for $BGNE, according to the investment firm's analysis.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login